| Search Weight Loss Topics: |
Posted: October 17, 2019 at 7:44 am
Report Testosterone Replacement Therapy covers all aspects of the "Testosterone Replacement Therapy Market". Continue reading
Posted: October 16, 2019 at 4:49 pm
The globalTestosterone Replacement Therapy marketrides on the back of technology. As consumer focus shifts from access to comfort, players in the market for Testosterone Replacement Therapy are looking at new opportunities to capitalize on the potential Continue reading
Posted: October 15, 2019 at 8:44 pm
Medical clinics across the country are advertising a treatment some believe is a fountain of youth. They're selling hormone therapy as a way to make people look and feel younger. Continue reading
Posted: October 11, 2019 at 10:51 am
The Testosterone Replacement Therapy market 2019 examines the global Testosterone Replacement Therapy market from a competitive outlook as well. Continue reading
Posted: October 11, 2019 at 10:51 am
Feeling tapped out. Foggy. Just not all that into sex. Continue reading
Posted: October 11, 2019 at 10:51 am
Introduction Mereo BioPharma (MREO) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, and ovarian cancer, respectively. The focus of this article is BGS-649 (leflutrozole), a drug asset licensed from Novartis (NVS) that is in clinical development for treating hypogonadotropic hypogonadism (Hypo-H). Continue reading
Posted: October 11, 2019 at 10:51 am
Report Testosterone Replacement Therapy covers all aspects of the "Testosterone Replacement Therapy Market". It provides basic market terminology and advanced analytical information in an understandable way that can be interpreted not just by a specialist but also a layman. Continue reading
Posted: October 11, 2019 at 10:51 am
We, Market Research Store, after comprehensive analysis, have introduced a new research study on "Global (United States, China, and European Union) Testosterone Replacement Therapy Market Research Report 2019-2025." A section of the report serves with in-depth information on Product Types [Gels, Injections, Patches], Applications [Hospitals, Clinics] and Key Players [AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals] Another section of the report particularly focuses on delivering wide-ranging analytical information on regional segmentation, which includes North America, Asia-Pacific, Middle East & Africa, Europe, and Rest of the World. Apart from this, manufacturing protocols, costing, development plans & policies, current trends, dynamics, clear market terminologies, and classifications, are very well described in the report. Continue reading
Posted: October 11, 2019 at 10:51 am
Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Continue reading
Posted: October 7, 2019 at 2:44 pm
The most common treatment for low testosterone (also called male hypogonadism) is testosterone replacement therapy. Continue reading
